skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 111,062  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: subject: Stockholders remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Transparency and reproducibility in artificial intelligence
Transparency and reproducibility in artificial intelligence
Material Type:
Article 		Add to My Research

Transparency and reproducibility in artificial intelligence

Nature (London), 2020-10, Vol.586 (7829), p.E14-E16 [Peer Reviewed Journal]

COPYRIGHT 2020 Nature Publishing Group ;Copyright Nature Publishing Group Oct 15, 2020 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-020-2766-y ;PMID: 33057217

Full text available

Citations Cited by
2
The Immune Landscape of Cancer
The Immune Landscape of Cancer
Material Type:
Article 		Add to My Research

The Immune Landscape of Cancer

Immunity (Cambridge, Mass.), 2018-04, Vol.48 (4), p.812-830.e14 [Peer Reviewed Journal]

2018 The Authors ;Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Apr 17, 2018 ;ISSN: 1074-7613 ;EISSN: 1097-4180 ;DOI: 10.1016/j.immuni.2018.03.023 ;PMID: 29628290

Full text available

Citations Cited by
3
Research in Focus: Gates MRI
Research in Focus: Gates MRI
Material Type:
Article 		Add to My Research

Research in Focus: Gates MRI

The Lancet (British edition), 2024-03, Vol.403 (10432), p.1126-1126 [Peer Reviewed Journal]

2024 Elsevier Ltd ;2024. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(24)00580-4 ;PMID: 38522439

Full text available

Citations Cited by
4
OP0043 IMPACT OF CARDIOVASCULAR COMORBIDITIES ON EFFICACY OF TOFACITINIB VS TNFI IN RHEUMATOID ARTHRITIS
OP0043 IMPACT OF CARDIOVASCULAR COMORBIDITIES ON EFFICACY OF TOFACITINIB VS TNFI IN RHEUMATOID ARTHRITIS
Material Type:
Article 		Add to My Research

OP0043 IMPACT OF CARDIOVASCULAR COMORBIDITIES ON EFFICACY OF TOFACITINIB VS TNFI IN RHEUMATOID ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.27-28 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2688

Full text available

Citations Cited by
5
AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY
AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY
Material Type:
Article 		Add to My Research

AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1765-1766 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2516

Full text available

Citations Cited by
6
POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY
POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY
Material Type:
Article 		Add to My Research

POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1137-1137 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2581

Full text available

Citations Cited by
7
POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES
POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES
Material Type:
Article 		Add to My Research

POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.345-346 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.464

Full text available

Citations Cited by
8
AB1096 IMPROVEMENT IN KEY PSORIATIC ARTHRITIS CORE DOMAINS WITH GUSELKUMAB TREATMENT IN AN ENRICHED POPULATION OF ACR20 NON-RESPONDERS AT WEEK 24: POST HOC ANALYSIS OF TWO PHASE 3 STUDIES
AB1096 IMPROVEMENT IN KEY PSORIATIC ARTHRITIS CORE DOMAINS WITH GUSELKUMAB TREATMENT IN AN ENRICHED POPULATION OF ACR20 NON-RESPONDERS AT WEEK 24: POST HOC ANALYSIS OF TWO PHASE 3 STUDIES
Material Type:
Article 		Add to My Research

AB1096 IMPROVEMENT IN KEY PSORIATIC ARTHRITIS CORE DOMAINS WITH GUSELKUMAB TREATMENT IN AN ENRICHED POPULATION OF ACR20 NON-RESPONDERS AT WEEK 24: POST HOC ANALYSIS OF TWO PHASE 3 STUDIES

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1772-1773 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.632

Full text available

Citations Cited by
9
AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Material Type:
Article 		Add to My Research

AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1782-1783 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.642

Full text available

Citations Cited by
10
AB1092 GUSELKUMAB RAPIDLY IMPROVES ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ACTIVE PSA: POOLED ANALYSIS OF 2 PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
AB1092 GUSELKUMAB RAPIDLY IMPROVES ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ACTIVE PSA: POOLED ANALYSIS OF 2 PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
Material Type:
Article 		Add to My Research

AB1092 GUSELKUMAB RAPIDLY IMPROVES ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ACTIVE PSA: POOLED ANALYSIS OF 2 PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1768-1769 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.365

Full text available

Citations Cited by
11
AB1095 IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB
AB1095 IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB
Material Type:
Article 		Add to My Research

AB1095 IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1771-1772 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.555

Full text available

Citations Cited by
12
POS0027 INDIVIDUAL ENTHESEAL POINTS HAVE DIFFERENTIAL FREQUENCY OF INVOLVEMENT AND IMPACT ON PATIENT REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
POS0027 INDIVIDUAL ENTHESEAL POINTS HAVE DIFFERENTIAL FREQUENCY OF INVOLVEMENT AND IMPACT ON PATIENT REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
Material Type:
Article 		Add to My Research

POS0027 INDIVIDUAL ENTHESEAL POINTS HAVE DIFFERENTIAL FREQUENCY OF INVOLVEMENT AND IMPACT ON PATIENT REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.220-221 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.122

Full text available

Citations Cited by
13
POS1535 EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT
POS1535 EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT
Material Type:
Article 		Add to My Research

POS1535 EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1131-1132 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1690

Full text available

Citations Cited by
14
AB1084 GUSELKUMAB PROVIDES RAPID CLINICALLY MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT REPORTED OUTCOMES AND SUSTAINED DISEASE CONTROL OF PSORIATIC ARTHRITIS
AB1084 GUSELKUMAB PROVIDES RAPID CLINICALLY MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT REPORTED OUTCOMES AND SUSTAINED DISEASE CONTROL OF PSORIATIC ARTHRITIS
Material Type:
Article 		Add to My Research

AB1084 GUSELKUMAB PROVIDES RAPID CLINICALLY MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT REPORTED OUTCOMES AND SUSTAINED DISEASE CONTROL OF PSORIATIC ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1762-1763 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.515

Full text available

Citations Cited by
15
AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Material Type:
Article 		Add to My Research

AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1765-1765 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1918

Full text available

Citations Cited by
16
Third-Line Therapy in Metastatic Colorectal Cancer
Third-Line Therapy in Metastatic Colorectal Cancer
Material Type:
Article 		Add to My Research

Third-Line Therapy in Metastatic Colorectal Cancer

The New England journal of medicine, 2023-07, Vol.389 (2), p.190-191 [Peer Reviewed Journal]

Copyright © 2023 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc2306486 ;PMID: 37437152

Full text available

Citations Cited by
17
Key audit risks and audit procedures during the initial year of the COVID-19 pandemic: an analysis of audit reports 2019-2020
Key audit risks and audit procedures during the initial year of the COVID-19 pandemic: an analysis of audit reports 2019-2020
Material Type:
Article 		Add to My Research

Key audit risks and audit procedures during the initial year of the COVID-19 pandemic: an analysis of audit reports 2019-2020

Managerial auditing journal, 2022-09, Vol.37 (7), p.798-818 [Peer Reviewed Journal]

Emerald Publishing Limited ;Emerald Publishing Limited. ;ISSN: 0268-6902 ;EISSN: 1758-7735 ;DOI: 10.1108/MAJ-07-2021-3225

Full text available

Citations Cited by
18
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
Material Type:
Article 		Add to My Research

Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Nature medicine, 2022-04, Vol.28 (4), p.626-629 [Peer Reviewed Journal]

Springer Nature America, Inc. 2022. ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-022-01681-x ;PMID: 35347282

Full text available

Citations Cited by
19
AB1094 GUSELKUMAB EFFECT ON INFLAMMATORY CARDIOVASCULAR (CV) RISK BIOMARKERS, EFFICACY, AND SAFETY IN PSORIATIC ARTHRITIS PATIENTS WITH CV RISK FACTORS: POST-HOC ANALYSIS OF 2 PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
AB1094 GUSELKUMAB EFFECT ON INFLAMMATORY CARDIOVASCULAR (CV) RISK BIOMARKERS, EFFICACY, AND SAFETY IN PSORIATIC ARTHRITIS PATIENTS WITH CV RISK FACTORS: POST-HOC ANALYSIS OF 2 PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
Material Type:
Article 		Add to My Research

AB1094 GUSELKUMAB EFFECT ON INFLAMMATORY CARDIOVASCULAR (CV) RISK BIOMARKERS, EFFICACY, AND SAFETY IN PSORIATIC ARTHRITIS PATIENTS WITH CV RISK FACTORS: POST-HOC ANALYSIS OF 2 PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1770-1771 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.512

Full text available

Citations Cited by
20
For whom does it pay to be a moral capitalist? Sustainability of corporate financial performance of ESG investment
For whom does it pay to be a moral capitalist? Sustainability of corporate financial performance of ESG investment
Material Type:
Article 		Add to My Research

For whom does it pay to be a moral capitalist? Sustainability of corporate financial performance of ESG investment

PloS one, 2023-05, Vol.18 (5), p.e0285027-e0285027 [Peer Reviewed Journal]

Copyright: © 2023 Gubareva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ;COPYRIGHT 2023 Public Library of Science ;2023 Gubareva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 Gubareva et al 2023 Gubareva et al ;2023 Gubareva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0285027 ;PMID: 37126520

Full text available

Citations Cited by

Results 1 - 20 of 111,062  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 1992  (9)
  2. 1992 To 2000  (32)
  3. 2001 To 2008  (332)
  4. 2009 To 2017  (4,797)
  5. After 2017  (105,903)
  6. More options open sub menu

Subject 

  1. Medical Research  (110,779)
  2. Biotechnology Industry  (89,161)
  3. Earnings Per Share  (61,453)
  4. Stock Exchanges  (59,443)
  5. Net Losses  (40,085)
  6. Current Liabilities  (36,789)
  7. Pharmaceutical Industry  (24,213)
  8. Capital Losses  (21,231)
  9. Corporate Profits  (19,524)
  10. Present Value  (19,359)
  11. Archives & Records  (18,973)
  12. Business Metrics  (16,975)
  13. Capital Gains  (15,235)
  14. Investments  (14,132)
  15. Annual Reports  (14,024)
  16. Research & Development  (14,001)
  17. R&d  (14,000)
  18. Book Value  (13,940)
  19. Short Sales  (13,822)
  20. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait